Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

The Danish drugmaker said a clinical trial showed participants who got a pill form of Wegovy lost an average of 16.6 percent ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

The results of this landmark trial are particularly significant, as oral therapies for obesity could improve both access to ...

Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with ...